Ceralasertib (** Currently experimental (no approved brand names); developed by AstraZeneca under the research designation AZD6738. **)

Description

Ceralasertib (also known as AZD6738) is an experimental drug currently being studied in clinical trials for certain advanced cancers. In colorectal cancer, it is being investigated specifically in combination with trastuzumab deruxtecan for tumors that express HER2 (a protein found on some cancer cells). The trials are looking at its safety, how it affects the body (pharmacokinetics), and its potential anti-tumor activity. These trials are in early phases (Phase 1), meaning they primarily focus on determining safe dosages and understanding how the drug works in patients. Ceralasertib is being studied in patients whose tumors have specific genetic changes, including HER2 expression, HER2 amplification, HER2 mutation, ATM mutation, and TP53 mutation.

Mechanism of Action

Ceralasertib is being studied as a targeted therapy. It works by inhibiting a protein called ATR (ATM and Rad3-related). ATR is involved in the DNA damage response pathway, helping cancer cells repair damaged DNA so they can continue to grow and divide. By blocking ATR, ceralasertib may make cancer cells more sensitive to other treatments, like trastuzumab deruxtecan, or potentially stop their growth on its own. The specific molecular target is being characterized in clinical trials.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials